To assess whether FRAX486 treatment rescues CDKL5‐dependent neurodevelopmental alterations, we first tested its effects on primary hippocampal cultures from Cdkl5‐KO mice, a reliable in vitro disease‐related model that recapitulates many of the most striking neuronal CDD phenotypes.30, 31, 32, 43. The gene discussed is CDKL5; the disease is craniodiaphyseal dysplasia.